ABSTRACT
Poly(lactic-co-glycolic) acid (PLGA) is a copolymer of polylactic acid (PLA) and polyglycolic acid (PGA), broadly used for the biomedical applications. In the last few decades, it is proven to be a most successful polymeric vehicle used for drug delivery and therefore approved by various regulatory agencies, namely USFDA and EMA. The commercial and clinical success of PLGA is due to unique characteristics such as biocompatibility, biodegradability, high drug entrapment capacity and surface modification possibilities. Various grades of PLGA provide flexibility among scientists to develop formulations of desired release characteristics. Extensive research done so far has depicted the application of PLGA-based carrier systems (microspheres, implants and nanoparticles) for controlled and targeted delivery of small-molecule drugs, proteins, peptides and monoclonal antibodies and other macromolecules for the treatment of various diseases. Apart from drug delivery, PLGA also proved its application in theranostic purposes where it can be attached to a contrast agent for phototherapy along with chemotherapy.. Despite multiple advantages, the usage of PLGA-based complex systems is restricted due to various limitations such as manufacturing/scale-up issue, insufficient regulatory guidance, the lack of trained manpower and IP-related issues. Considering the potential of this polymer for drug delivery and proven clinical application, it became highly important to strengthen the capabilities for the development and manufacturing of PLGA-based carrier systems. This chapter deals with information and discussion of applications of PLGA from lab to clinic with key highlights on associated challenges.
